Lipiodol | Lipiodol+EmboCept®S | p-value | |
---|---|---|---|
Number of patients | 51 | 48 | 0.584 |
➢ female | 13 | 8 | |
➢ male | 38 | 40 | |
Age of patients (years) | 63.8 | 63.4 | 0.972 |
Number of TACE | 283 | 384 | 0.421 |
Presence of liver cirrhosis (%) | 38 | 53 | |
Initial liver disease: | |||
Hepatitis B | 10 | 19 | |
Hepatitis C | 23 | 13 | |
Hepatitis B and C | 6 | 3 | 0.643 |
Hemochromatosis | 1 | 2 | |
Alcohol abusus | 13 | 13 | |
BCLC-Stage: | |||
BCLC-Stage A | 3 | 5 | 0.194 |
BCLC-Stage B | 35 | 56 | |
Child-Pugh class: | |||
A | 9 | 18 | 0.206 |
B | 36 | 36 | |
Localisation in liver: | |||
Right lobar | 22 | 23 | |
Left lobe | 3 | 2 | 0.310 |
Bilobar | 19 | 30 | |
Number of tumor lesions: | |||
Single | 8 | 3 | |
2 | 28 | 0 | |
3 | 8 | 0 | 0.252 |
4 | 4 | 0 | |
Multifocal | 0 | 48 | |
Tumor response: | |||
Partial response | 11 | 14 | 0.211 |
Stable disease | 32 | 22 | |
Progressive disease | 8 | 12 |